Last summer PhRMA reported there are 19 stroke drugs in clinical trials, with GlaxoSmithKline, Pfizer and Sanofi all vying to bring a product to market. Recent history suggests many of these compounds will flunk Phase III trials, but if a robotics team at MIT has its way the failures will at least be faster and cheaper than in the past.
The United Kingdom's public healthcare system has long used its cradle-to-grave records to advance research. Now, the government plans to digitize its health record treasure trove and sell access to biopharma companies.
As part of Horizon 2020, the European Union's $100 billion initiative to secure the competitiveness of the region through investment in innovative projects, the EU is setting aside an initial $40 million for companies that can turn data into discoveries.
The framework underpinning the game has been through one pilot project and is on to a second. Merck is now evaluating the game. Players create an avatar and then complete minigames to win gold coins.
The United Kingdom is moving heavily into sequencing through its 100K Genome Project, but the data is of little use without analytical abilities. With this in mind, the U.K. government has coughed up an extra $16 million to find genomics sequence data analysis and interpretation tools.
Poor returns led drug developers to exit the antibiotics sector years ago, only for hospital-acquired infections to become a big, deadly and potentially lucrative problem. Big Pharma is returning to the sector, but two academics have a different idea: crowdsource discovery.
With researchers estimating that as many as 70% of new chemical entities (NCEs) are poorly soluble in water, service providers have scrambled to offer drug delivery technologies that improve bioavailability. But which is right for your active ingredient? Catalent has created software to help answer this question.
Open-source software developers have long stood on the shoulders of giants, incorporating existing tools where possible so they can focus resources on improving other areas. And with the proliferation of open-source genomics programs, Biodatomics is betting on the model working for bioinformatics.
The software is the result of a three-year effort by Rhenovia and its collaborators to develop a computer model for epilepsy that is validated by laboratory experiments. Having created the software, Rhenovia is looking to market it to biopharma companies. The platform could help identify new therapeutic candidates--or reposition existing molecules--and assess their toxicology and safety profiles.
Recognition of the role of protein structure changes in signaling has driven a proliferation of techniques to detect the shifts. Crystallography, dual polarization interferometry and a host of other methods have been tried, but all have flaws. Now, Pfizer and Roche think they have found a better way.